These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31609520)

  • 21. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
    Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE
    Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients.
    Luckett K; Kaiser TE; Bari K; Safdar K; Schoech MR; Apewokin S; Diwan TS; Cuffy MC; Anwar N; Shah SA
    J Am Coll Surg; 2019 Apr; 228(4):560-567. PubMed ID: 30586641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.
    Jiménez-Romero C; Justo I; Marcacuzco A; García V; Manrique A; García-Sesma Á; Calvo J; Fernández I; Martín-Arriscado C; Caso Ó
    Int J Surg; 2021 Jul; 91():105981. PubMed ID: 34098075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
    Mazur RD; Goldberg DS
    Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation.
    Burton JR; Terrault NA; Goldberg DS; Bloom RD; Gilroy R; Heimbach JK; Brown RS; Everson GT; Rubin E; Wiesner R; Pomfret EA
    Transplantation; 2020 Mar; 104(3):476-481. PubMed ID: 31634329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?
    Trotter PB; Summers DM; Ushiro-Lumb I; Robb M; Bradley JA; Powell J; Watson CJE; Neuberger J
    Transplantation; 2018 Apr; 102(4):664-672. PubMed ID: 29166338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience.
    Ofosu A; Durand CM; Saberi B; Alqahtani S; Ucbilek E; Belden M; Cameron AM; Gurakar A
    Exp Clin Transplant; 2015 Nov; 13 Suppl 3():7-10. PubMed ID: 26640901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preemptive antiviral therapy in lung transplantation from hepatitis C donors results in a rapid and sustained virologic response.
    Villavicencio MA; Li SS; Leifer AM; Gustafson JL; Osho A; Wolfe S; Raz Y; Griffith J; Neuringer I; Bethea E; Gift T; Waldman G; Astor T; Langer NB; Chung RT
    JTCVS Open; 2023 Jun; 14():602-614. PubMed ID: 37425441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome.
    Nair SP; Marella HK; Maliakkal B; Snyder H; Handley C; Kothadia JP; Ali B; Satapathy SK; Molnar MZ; Clark I; Jain R; Helmick R; Eymard C; Eason JD
    Clin Transplant; 2021 May; 35(5):e14281. PubMed ID: 33690929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Experiment of Nature: HBV-naive Recipients Receiving Liver Grafts With HBV Core Antibody-positive Donors Without Antiviral Prophylaxis.
    Fallahzadeh MA; Trotter JF
    Transplantation; 2020 Aug; 104(8):e245-e246. PubMed ID: 32732858
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Terrault NA; Burton J; Ghobrial M; Verna E; Bayer J; Klein C; Victor D; Mohan S; Trotter J; Dodge J; Niemann CU; Rubin RA
    Hepatology; 2021 Jun; 73(6):2110-2123. PubMed ID: 32926749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes After Direct-Acting Antiviral Therapy Based on Donor Hepatitis C Serostatus Among Hepatitis C Virus-Infected Kidney Transplant Recipients.
    Sedki M; Cortesi C; O'Brien C; Levy C; Martin P; Roth D; Bhamidimarri KR
    Exp Clin Transplant; 2020 Mar; ():. PubMed ID: 32133941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review.
    Shadekejiang H; Zhu J; Wu X
    Exp Clin Transplant; 2022 Dec; 20(12):1076-1084. PubMed ID: 36718006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients.
    Saab S; Barnard A; Challita Y; Adeniyi A; Aziz A; Choi G; Durazo FA; El-Kabany MM; Han SB; Busuttil RW
    Exp Clin Transplant; 2018 Aug; 16(4):419-424. PubMed ID: 30060729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.